The South African subsidiary of Indian generic giant Hetero has launched an urgent legal attack against the Department of Health over its latest HIV/AIDS drug tender. Hetero SA alleges that authorities unlawfully excluded it from crucial contracts to supply the primary “three-in-one” pill (TLD) used by most of South Africa’s 5.6 million patients. Just as new contracts start on 1…